21 May 2013
Keywords: solvay, discontinues, cb1, obesity, drug, slv319, belgian
Article | 24 November 2008
Belgian drugmaker Solvay Pharmaceuticals has discontinued all R&D activities for SLV319, a selective cannabinoid type 1 antagonist, that
was in ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
24 November 2008
20 May 2013
© 2013 thepharmaletter.com